key: cord-0787580-bi4cag63
authors: Wang, Juan; Liang, Boqiang; Chen, Yiling; Fuk-Woo Chan, Jasper; Yuan, Shuofeng; Ye, Hui; Nie, Linlin; Zhou, Jiao; Wu, Yi; Wu, Meixian; Huang, Lina S.; An, Jing; Warshel, Arieh; Yuen, Kwok-Yung; Ciechanover, Aaron; Huang, Ziwei; Xu, Yan
title: A new class of α-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities
date: 2021-02-10
journal: Eur J Med Chem
DOI: 10.1016/j.ejmech.2021.113267
sha: 721912c4af5cc8a8fa1849f0af3e2e5d01a1ad3c
doc_id: 787580
cord_uid: bi4cag63

Inhibitors of the proteasome have been extensively studied for their applications in the treatment of human diseases such as hematologic malignancies, autoimmune disorders, and viral infections. Many of the proteasome inhibitors reported in the literature target the non-primed site of proteasome's substrate binding pocket. In this study, we designed, synthesized and characterized a series of novel α-keto phenylamide derivatives aimed at both the primed and non-primed sites of the proteasome. In these derivatives, different substituted phenyl groups at the head group targeting the primed site were incorporated in order to investigate their structure-activity relationship and optimize the potency of α-keto phenylamides. In addition, the biological effects of modifications at the cap moiety, P1、P2 and P3 side chain positions were explored. Many derivatives displayed highly potent biological activities in proteasome inhibition and anticancer activity against a panel of six cancer cell lines, which were further rationalized by molecular modeling analyses. Furthermore, a representative α-ketoamide derivative was tested and found to be active in inhibiting the cellular infection of SARS-CoV-2 which causes the COVID-19 pandemic. These results demonstrate that this new class of α-ketoamide derivatives are potent anticancer agents and provide experimental evidence of the anti-SARS-CoV-2 effect by one of them, thus suggesting a possible new lead to develop antiviral therapeutics for COVID-19.

The ubiquitin−proteasome system (UPS) plays essential roles in the turnover of numerous cellular proteins involved in cell cycle, signal transduction, antigen processing, protein quality control, etc [1] . The proteasome, an ATP dependent multi-subunit complex, is a central mediator of proteolysis in UPS. Diverse hybrid forms of proteasome have been identified. In general, the hybrid proteasome is composed of two parts: 20S core particle (CP) and regulatory particle (RP) including PA700 (or the 19S cap), PA28 (also known as 11S), and Blm10/PA200 protein. One 20S core particle binds with one or two regulatory particle to form singly (RP1-CP) or doubly (RP2-CP) hybrid proteasome, respectively [2, 3] .

26S proteasome is the most common form of proteasome, consisting of 20S core particle capped with two 19S regulatory particles [4] . The 19S regulatory particle is responsible for the ubiquitylated substrate recognition, deubiquitination, unfolding, and translocation of the unfolded chain into the core particle. The catalytic domain resides in the 20S core particle that is associated with the degradation of damaged proteins and cell signaling proteins. The 20S core particle consists of four stacked rings, with two outer rings composed of seven α subunits and two inner rings composed of seven β subunits [5, 6] . The catalytic subunits β5, β2 and β1 reside in the inner β ring that exhibits chymotrypsin-like (CT-L), trypsin-like (T-L) and caspase-like (C-L) proteolytic activity, respectively [7] . In vertebrates, three isoforms of the 20S CP have been identified, including constitutive proteasome (cCP) which harbors β1c, β2c and β5c, immunoproteasome (iCP) which harbors β1i (LMP2), β2i (MECL-1) and β5i (LMP7), thymoproteasome (tCP) which harbors β1i, β2i and β5t [8, 9] . The immunoproteasome is involved in antigen processing that influences cytokine production and T cell function [10] .

Overexpression of immuno-and constitutive proteasome is observed in hematologic malignancies and autoimmune diseases. Different classes of proteasome inhibitors have been developed for clinical intervention of hematologic malignancies and autoimmune disorders [11] [12] [13] .

Although many proteasome inhibitors including those clinically approved drugs such as bortezomib [14, 15] , carfilzomib [16] , and ixazomib [17] have been developed that mostly target the non-primed substrate binding site of proteasome ( Figure 1A ), few proteasome inhibitors targeting both non-primed and primed sites or only the primed site of the substrate binding pocket have been reported. Among them, dipeptide α,β epoxyketone UK-101 ( Figure 1B) showing good selectivity for β1i subunit binds both non-primed and primed sites [18] . β-Lactone homobelactosin C primarily binds to the primed site exhibiting high potency to β5 subunit [19, 20] . A recent study has shown that epoxyketone-based compounds targeting P1′ site have the efficacy against cell lines of de novo or acquired resistance to carfilzomib [21] . Thus, discovery of new compounds capable of binding the primed site remains an area to be explored further.

It has been reported that a ketoamide derivative BSc2189 ( Figure 1A ) binds to the active site in the 20S proteasome in a reversible manner [22] [23] [24] . Its phenyl group at the head group occupies the primed substrate binding channel of 20S proteasome ( Figure 1A ) [24] . Previous studies have utilized the primed site to improve the specificity and potency of protease inhibitors [25] [26] [27] . In this study, we incorporated different substitutions into α-keto phenylamide's head group to examine their effects on the proteasome inhibitory potency. Additional modifications were also made on the cap moiety and the P1、P2 and P3 side chain positions of α-keto phenylamide to investigate the influence of these positions on bioactivity. These modification studies should J o u r n a l P r e -p r o o f yield insight into the structure-activity relationship (SAR) of α-ketoamide-based proteasome inhibitors which has not been reported before. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel betacoronavirus which causes the ongoing Coronavirus Disease 2019 (COVID-19) pandemic [28] . Currently, antiviral treatment options for COVID-19 are limited. Thus, the development of effective drugs is an urgent challenge. Previous studies have shown that proteasome inhibitors can inhibit J o u r n a l P r e -p r o o f coronavirus replication by interfering with the early steps of the viral replication cycle [29, 30] .

For example, the proteasome inhibitor MG132 ( Figure 1B ) and its analogs have been reported to have inhibitory activity against severe acute respiratory syndrome coronavirus (SARS-CoV) [31, 32] . Mice infected with mouse hepatitis virus 1 and treated with MG132 had higher survival rate, less severe lung histopathological changes, and reduced lung virus replication, lung STAT phosphorylation, and expression of pneumoinflammatory cytokines. The anti-coronaviral effect of MG132 was suggested to be due to its inhibition of viral replication-dependent cysteine protease m-calpain [31] . Because of the high homology between SARS-CoV-2 and SARS-CoV [33, 34] , we hypothesized that proteasome inhibitors capable of blocking SARS-CoV may also be effective against SARS-CoV-2. To test this hypothesis, we examined the anti-SARS-CoV-2 activity of one of the α-ketoamide derivatives reported here, chosen based on its low toxicity compared with others in Vero E6 cells which was used for SARS-CoV-2 infection assay. This representative analog showed potent inhibition of SARS-CoV-2 infection, thus demonstrating experimentally that this and potentially some of the other α-ketoamide derivatives reported here may have the potential for the development of anti-SARS-CoV-2 agents.

The general synthetic route is shown in Schemes 1-2. In general, amino acid methyl ester 1 was coupled with Boc protected amino acid to afford 2a-b or Cbz protected amino acid to afford 9a-c using HATU as the coupling reagent. The Boc group of 2a-b was removed using trifluoroacetic acid (TFA) and the resulting compound then coupled with commercially available carboxylic acid derivatives except for carboxylic acid 16 which was prepared in our lab (Scheme J o u r n a l P r e -p r o o f 7 2), affording compounds 4a-b. Compounds 4a-b or 9a-c were hydrolyzed to give 5a-b or 10a-c.

Acid 5a-b with different cap moieties or acid 10a-c with Cbz cap moiety were coupled with Lleucinol in the presence of isobutyl chloroformate and N-methylmorpholine to yield intermediate 6a or 11a-c. 6a or 11a was oxidated into 7a or 12a using 2-iodoxybenzoic acid. Aldehyde 7a or 12a reacted with appropriate isonitrile by Passerini reaction method to generate 8a or 13a, which was subsequently oxidized to the desired target molecule with 2-iodoxybenzoic acid. 

All compounds were evaluated with a cell-based proteasome inhibition assay (Promega).

Because the β5 catalytic subunit is the primary target of these proteasome inhibitors [4] , all α-J o u r n a l P r e -p r o o f keto phenylamide derivatives were screened for their inhibition of chymotrypsin-like activity.

The biological activity of these derivatives is presented and discussed below in different groups according to the structural modifications made at the N-cap position, P1、P2 and P3 positions, and the head group.

Initially, we designed 18 and a hybrid compound 17 which contains the peptide backbone of a β5i-selective inhibitor ONX-0914 [11] and the head group of BSc2189 [24] . 

The phenylamide group of BSc2189 could form π-alkyl interaction with Ser129 in β5's primed site. In previous work by others, different electron donating groups such as methyl and electron withdrawing groups such as cyano were incorporated into the para position of phenylamide group [24] , which found that compound BSc4999 with 2, 4-dimethyl phenylamide was about 2 fold more potent than BSc2189 with an unsubstituted phenylamide whereas most of other compounds showed decreased activity towards chymotrypsin-like subunit compared with

BSc2189.

Here, we focused on using primed site to improve the potency. Phenyl group at the head position was deemed to be a suitable starting point to introduce various modifications. Various groups at the ortho and meta positions of phenylamide group were introduced based on different tripeptide scaffolds (Table 3) . (Table 3) . The SAR results shown above suggested that a substituted aromatic ring at the cap moiety, Leu at the P1 position, Trp or Leu at the P2 position, Leu at the P3 position, and 3-acetylphenyl or 3,5-dimethoxyphenyl at the head group are favored for β5/CT-L inhibitory activity. Based on this pharmacophore, we further designed two hybrid molecules, 45 and 46 with all these features ( Table 3 ). Both of them displayed potent inhibition of β5. In addition, the 3-methoxyphenyl at the head position (47) showed strong activity with an IC 50 value of 28.8 nM against β5.

In addition to β5, the activity of representative compounds, 35, 44 and 46 and control compound BSc2189 was determined against β1 and β2 in cell-based caspase-like and trypsinlike activity assay ( Figure 2 ). All of these compounds were more active against the β2 subunit than the β1 subunit. 44 and 46 had a low nanomolar IC 50 for the trypsin-like subunit (β2).

Recently others reported that dual inhibition of β2 and β5 activity could achieve maximum proteasome inhibition and was most effective in proteasome inhibitor-resistant multiple myeloma [38] . In light of this, 44 and 46 displaying activity in both β2 and β5 may merit further studies. 

Based on the results of cell-based proteasome inhibition assays shown above in Tables 1-3, a group of 7 compounds were selected for their more potent proteasome inhibitory activities than others and for representing modifications at different sites (the head group and cap moiety). (Table 4 ). We also determined the IC 50 values of those compounds that exhibited ≥ 50% inhibition of RPMI8226 at 1 μM (Supplemental Table S1 ). The results indicated good correlation between proteasome inhibition potency and anticancer activity.

All tested compounds were highly effective on hematologic tumor cell lines RPMI8226, Ramos and THP-1. The IC 50 of control compound BSc2189 was 288 nM in HeLa cells which was in consistent with its previously published value of 254 nM [23] . 46 was the most potent compound in both cell-based proteasome inhibition and cancer cell viability assays. which may be related with their higher β5i selectivity [39, 40] . 

After determining the potent anticancer activity of our new α-ketoamide derivatives, in response to the most recent COVID-19 global pandemic caused by SARS-CoV-2, we decided to test the hypothesis as described above that some of these compounds may possess anti-SARS-CoV-2 activity. We first tested the cytotoxicity of several representative derivatives in Vero E6 Table S2 ). Compound 17 was found to be the least toxic and subsequently tested in Caco-2 cells also. We selected compound 17 for antiviral study using a plaque reduction assay to determine the 50% antiviral effective dose (EC 50 ) of the compound. In the plaque reduction assay, Vero E6 cells were seeded at 4×10 5 cells/well in 12-well tissue culture plates on the day before carrying out the assay. 

The SAR of the synthesized compounds was further studied by CoMFA using a selected set of 25 compounds with diverse chemical structures and distribution of bioactivities. The data set was divided into a training set (20 compounds) for model development and a test set (5 compounds) for model validation. Selection of the test set compounds was made based on structural and biological diversity. These compounds are shown in Supplemental Table S3 . The calculation method is described in the method section.

The CoMFA model has good cross-validated correlation with a q 2 value of 0.537 with 4 optimum components. The correlation coefficient r 2 is 0.959, and the predicted correlation coefficients r 2 pred is 0.814, which reveals that the CoMFA model has high predictive capability.

The plots of predicted versus actual activity for all the data set are shown in Supplemental Figure   S1 . As to the steric and electrostatic field contribution, the former accounts for 0.714 while the latter 0.286, indicating that the steric factor contributes more to the binding affinities.

The CoMFA contour map is shown in Figure 4 . The cap position is highlighted in green color, which indicates that bulky substituents in this area may improve the activity. The bioactivity of 5-(4-acetylphenyl) furan containing 26 is much higher than furan containing 23. The yellow area at the P2 position indicates that the activity can be improved by decreasing the size of the methoxyl group of the phenyl core. The green area around the isopropyl group shows that it plays an important role in the contribution to bioactivities. The isopropyl group at P2 position has higher bioactivity than an aromatic group such as a phenyl or indole ring. The blue area at the warhead region suggests that a positive charge on the phenyl core may improve the activity. Recent studies show that α-ketoamide derivatives such as boceprevir, narlaprevir [42] , and 13b [43] act as potent SARS-CoV-2 main protease inhibitors. Therefore, we also examined the potential docking of compound 17 to the active site of SARS-CoV-2 main protease ( Figure 6D ).

Docking models indicated that α-keto oxygen and the amide oxygen of α-ketoamide head group 

To the mixture of H-Leu-OMe·HCl (12.7 g, 69.9 mmol, 1.0 equiv), Boc-Leu-OH ( 

To a solution of Boc-Tyr(OMe)-OH (3.6 g, 12.19 mmol, 1.0 equiv) in dry methanol was added To a solution of 2b (3.7 g, 9.73 mmol, 1 equiv) in CH 2 Cl 2 (10 mL) was added TFA (11.08 To a solution of 2-morpholinoacetic acid (0.9 g, 6.21 mmol, 1.0 equiv) in THF was added HATU (2.6 g, 6.83 mmol, 1.1 equiv) and HOBt (0.9 g, 6.83 mmol, 1.1 equiv) subsequently. The reaction solution was cooled to 0 °C. Then 3b (2.6 g, 6.21 mmol, 1.0 equiv) was added. DIEA was added dropwise. The reaction mixture was stirred at -5 to 0 °C for 2 h. Water was added and the mixture was extracted with ethyl acetate. The organic layer was separated and the aqueous layer was extracted with ethyl acetate again. The combined organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated under vacuum. The crude product was purified by silica gel column to yield 6a or 11a-c. 

To a solution of 6a or 11a (1 equiv) in DMSO, IBX (1.5 equiv) was added. The resulting solution was stirred at room temperature for 4 h. The reaction mixture was partitioned between ethyl acetate (30 mL) and saturated NaHCO 3 (30 mL). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (2 × 30mL). The combined organic layer was washed with saturated NaHCO 3 and brine, dried over anhydrous sodium sulfate, filtered, concentrated under vacuum. The crude product was purified by silica gel column to yield 7a or 12a. 

The mixture of 3-aminoacetophenone ( The reaction solution was stirred for 2 h at room temperature. CH 2 Cl 2 and water was added. The water layer was separated, then adjusted pH to 3 with 2N HCl. The resulting mixture was extracted with ethyl acetate. The organic layers were combined, washed with brine, dried and concentrated under vacuum to give compound 16 (8.5 g, 89% yield) as off white solid.

To a solution of 7a or 12a (1.0 equiv) and 14 (1.5 equiv) in dry CH 2 Cl 2 (2 mL), trifluoroacetic acid (2.0 equiv) was added dropwise at -5 °C. The reaction mixture was allowed to stir for 2 h at J o u r n a l P r e -p r o o f 0 °C. Then pyridine (4.0 equiv) was added at 0 °C. The resulting solution was stirred at 0 °C for 1 h. CH 2 Cl 2 was added, the pH value of the reaction was adjusted to 5 ~ 6 with 1N HCl in ice bath. The aqueous layer was separated, the organic layer was washed with water (30 mL) and

brine (30 mL J o u r n a l P r e -p r o o f

White solid. Yield 21%. 1 

propanamido) 

propanamido) ( ( ( 

J o u r n a l P r e -p r o o f incubated for another 3 h at 37 °C. Optical density was determined at 490 nm by microplate reader. The assays were done in triplicate with triplicate wells per experiment. The IC 50 values were calculated by GraphPad Prism software.

Plaque reduction assay was performed to plot the 50% antiviral effective dose (EC 50 ) as we described previously with slight modifications [46] [47] [48] . Briefly, Vero E6 cells were seeded at 4×10 5 cells/well in 12-well tissue culture plates on the day before carrying out the assay. After After removal of the agarose plugs, the monolayers were stained with 0.7% crystal violet (BDH, Merck) and the plaques counted. The percentage of plaque inhibition relative to the control (i.e.

without the addition of compound) wells were determined for each drug compound concentration. The EC 50 was calculated using Sigma plot (SPSS) in an Excel add-in ED50V10.

The plaque reduction assay experiments were performed in triplicate and repeated twice for confirmation.

J o u r n a l P r e -p r o o f Before performing the above described plaque reduction assay, the CellTiterGlo luminescent assay (Promega Corporation, Madison, WI, USA) was conducted to detect the cytotoxicity of the selected compound as we described previously [49] . Briefly, Vero E6 cells and/or Caco-2 cells

(2 x 10 4 cells/well) were incubated with the serially diluted compound for 48 h, followed by addition of substrate and measurement of luminance 10 min according to manufacturer's protocol. The 50% cytotoxic concentrations (CC 50 ) of the drug were calculated by GraphPad

Prism software.

The CoMFA model is built by SYBYL_X 2.0 suite software (Tripos Inc., USA). The set of compounds (25 in total) are minimized with the Tripos force field and Gasteiger-Hückel charge.

The conformation of compound BSc2198 is used as the template, the other 24 compounds are aligned by fitting the three chiral carbon atoms. CoMFA descriptors calculation and partial leastsquares (PLS) model fitting are conducted in the QSAR module of SYBYL suite. SAMPLS with leave-one-out (LOO) are carried out to calculate the cross-validation value q 2 . The conventional correlation coefficient r 2 is then calculated with no validation using the optimum number of component. In order to improve reduce 'noise', a minimum filter value of 2.00 kcal/mol is used.

The covalent docking studies are performed with GOLD version 2020. The crystal structure of SARS-CoV-2 main protease (PDB: 6Y2F) [43] was used for compound 17 docking studies. The binding site was defined as 10 Å around the sulfur atom of Cys 145 .

ChemScore scoring function was used and the number of GA runs was 50 and the other parameters were set as defaults.

The 

s, 4H), 1.75-1.67 (m, 1H), 1.63-1.54 (m, 1H), 1.50-1.42 (m, 1H), 1.39-1.32 (m, 3H), 1.01-0.95 (m, 3H), 0.94-0.89 (m, 3H). HRMS (ESI): m/z (M + H) +

1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)carbamic acid benzyl ester (19) White solid

11 (d, J = 8.5 Hz, 2H), 6.86-6.74 (m, 2H), 6.63-6.41 (m, 2H), 5.39-5.28 (m, 1H)

1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)decanamide (20) White solid. Yield 56%

400 MHz, CDCl 3 ) δ 8.63 (s, 1H), 7.63 (d, J = 7.8 Hz, 2H), 7.37 (t, J = 7.9 Hz, 2H), 7.21-7.15 (m, 1H), 7.14-7.08 (m, 2H), 6.79 (d, J = 8.6 Hz, 2H), 6.58 (dd, J = 21.0, 7.7 Hz, 2H), 5.96-5.79 (m, 1H), 5.39-5.28 (m, 1H)

1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)carbamic acid tert-butyl ester (21) White solid. Yield 60%. 1 H NMR (400 MHz

Hz, 2H), 7.21 (t, J = 7.4 Hz, 1H), 7.14 (d, J = 8.6 Hz, 2H), 6.87-6.77(m, 2H), 6.61-6.54 (m, 1H)

(d, J = 96.3 Hz, 6H). HRMS (ESI): m/z (M + H) + calcd for

3-(4-methoxyphenyl)-1-(((S)-5-methyl-1,2-dioxo-1-(phenylamino)hexan-3-yl)

CDCl 3 ) δ 8.84 (s, 1H), 7.89-7.75 (m, 2H), 7.74-7.30 (m, 7H), 7.26-7.20 (m, 2H), 7.19-7.01 (m, 3H), 7.01-6.87 (m, 1H), 5.42-5.22 (m, 1H)

3-(4-methoxyphenyl)-1-(((S)-5-methyl-1,2-dioxo-1-(phenylamino)hexan-3-yl)

1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)5-(4-acetylphenyl)furan-2-carboxamide (26)

White solid. Yield 61%. 1 H NMR (400 MHz, CDCl 3 ) δ 8.63 (s, 1H), 8.03 (d, J = 8.5 Hz, 2H), 7.81 (d, J = 8.5 Hz, 2H), 7.63 (d, J = 7.7 Hz, 2H), 7.44-7.33 (m, 2H), 7.25-7.16 (m, 2H), 7.14-7.06 (m, 2H), 6.90 (d, J = 3.6 Hz, 1H), 6.83-6.77 (m, 1H), 6.75-6.65 (m, 3H), 6.56-6.43 (m, 1H), 5.41-5.31 (m, 1H

HRMS (ESI): m/z (M + H) + calcd for C 39 H 43 N 4 O 8

2-yl)amino)-1-oxopropan-2-yl)carbamic acid benzyl ester (27) White solid. Yield 20%. 1 H NMR (400 MHz, CDCl 3 ) δ 8.63-8.44 (m, 1H), 8.00-7.83 (m, 1H)

m, 6H), 7.29-7.26 (m, 1H), 7.25-7.24 (m, 1H), 7.23-7.01 (m, 3H), 6.76-6.56 (m, 1H), 6.49-6.35 (m, 1H), 5.36-5.23 (m, 1H

(S)-5-methyl-1,2-dioxo-1-(phenylamino)hexan-3-yl)amino)-1-oxopropan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamic acid benzyl ester (29) White solid

2-yl)amino)-1-oxopentan-2-yl)carbamic acid benzyl ester (30) White solid. Yield 48%. 1 H NMR (400 MHz, CDCl 3 ) δ 8.64 (s, 1H), 7.67-7.53 (m, 2H), 7.43-7.28 (m, 7H), 7.26-7.23 (m, 1H), 7.22-7

-methyl-1,2-dioxo-1-(phenylamino)hexan-3-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-1-oxopropan-2-yl

CDCl 3 ) δ 8.61 (s, 1H), 7.62 (d, J = 7.8 Hz, 2H), 7.43-7.29 (m, 6H), 7.25-7.22 (m, 2H), 7.21-7.13 (m, 3H), 6.59-6.43(m, 2H), 5.40-5.29 (m, 1H)

-phenylacetamido)propanamido)propanamido)-5-methyl-N-(naphthalen-1-yl)-2-oxohexanamide (33) White solid

-acetylphenyl)amino)-5-methyl-1,2-dioxohexan-3-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl) carbamic acid benzyl ester (38) White solid. Yield 21%. 1 H NMR (400 MHz, DMSO-d6)

yl)amino)-1-oxopentan-2-yl)amino)-1-oxopentan-2-yl)carbamic acid benzyl ester (39) White solid. Yield 27%. 1 H NMR (400 MHz, CDCl 3 ) δ 9.18 (s, 1H), 9.04-8.91 (m, 1H), 8.47-8.29(m, 1H), 8.25-8.08 (m, 2H), 7.87-7.72 (m, 1H), 7.65-7.50 (m, 1H), 7.39-7.31 (m, 3H), 7.30-7.27 (m, 1H), 7.20-6.88 (m, 1H)

isoquinolin-5-ylamino)-5-methyl-1,2-dioxohexan-3-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamic acid benzyl ester (40) White solid. Yield 16%. 1 H NMR (400 MHz, CDCl 3 ) δ 9.33 (s, 1H

-ylamino)-5-methyl-1,2-dioxohexan-3-yl)amino)-4-methyl-1-oxopentan-2-yl)amino

White solid. Yield 32%. 1 H NMR (400 MHz, CDCl 3 ) δ 8.89 (s, 1H), 8.52-8.43 (m, 1H), 7.55-7.27 (m, 11H), 7.26-7.18 (m, 1H), 6.96-6.60 (m, 1H), 6.41-6.21 (m, 1H), 5.46-5.35 (m, 1H), 5.14-5.05 (m, 2H

-ethylphenyl)amino)-5-methyl-1,2-dioxohexan-3-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamic acid benzyl ester (43) White solid. Yield 12%. 1 H NMR (400 MHz

1.85-1.47 (m, 9H), 1.25 (t, J = 7.6 Hz, 3H

5-dimethoxyphenyl)amino)-5-methyl-1,2-dioxohexan-3-yl)amino)-4-methyl-1-oxopentan-2-yl)amino

Yield 65%. 1 H NMR (400 MHz

Hz, 2H), 6.77-6.70(m, 1H), 6.45-6.33 (m, 1H), 6.31-6.27 (m, 1H), 5.46-5.32 (m, 1H), 5.16-5.07 (m, 2H)

5-dimethoxyphenyl)amino)-5-methyl-1,2-dioxohexan-3-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)5-(4-acetylphenyl)-furan-2-carboxamide (45) White solid. Yield 6%. 1 H NMR (400 MHz

= 8.4 Hz, 2H), 7.80 (d, J = 8.4 Hz, 2H), 7.25-7.23 (m, 1H), 6.89 (d, J = 3.6 Hz, 1H), 6.86-6.83 (m, 2H), 6.82-6.77 (m, 1H), 6.68 (d, J = 7.3 Hz, 1H), 6.57-6.51 (m, 1H), 6.31-6.27 (m, 1H), 5.46-5

-methoxyphenyl)amino)-5-methyl-1,2-dioxohexan-3-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)5-(4-acetylphenyl)-furan-2-carboxamide (47) White solid. Yield 11%. 1 H NMR (400 MHz

= 8.4 Hz, 2H), 7.81 (d, J = 8.5 Hz, 2H), 7.37-7.32 (m, 1H), 7.29-7.26(m, 1H), 7.25-7.23 (m, 1H), J o u r n a l P r e -p r o o f 7.15-7.07 (m, 1H)

All complexes are relaxed for 0.5 ns, with 1 fs time step. The simulations are conducted at 30 K. It should be noted that much more quantitative docking calculations can be performed in the future, combining the empirical valence bond (EVB) method and binding calculations

Supplemental data In vitro anti-proliferative activities of selected compounds against RPMI8226 in Table S1

Cytotoxicity of selected proteasome inhibitors on Vero E6 and Caco-2 in Table S2

ketoamide dericatives used for CoMFA analysis in Table S3

performed chemical syntheses and wrote the manuscript

Y. performed the proteasome inhibition and cancer cell toxicity experiments

performed anti-SARS-CoV-2 assays

A. and A.W. performed the molecular modeling studies and data analysis

The Ubiquitin System

The life cycle of the 26S proteasome: from birth, through regulation and function, and onto its death

Regulation of proteasome assembly and activity in health and disease

The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug Target

Structure of 20S proteasome from yeast at 2.4Å resolution

The multicatalytic proteinase complex, a major extralysosomal proteolytic system

The Mechanistic Links Between Proteasome Activity, Aging and Agerelated Diseases

Regulation of CD8 + T Cell Development by Thymus-Specific Proteasomes

Proteasomes in immune cells: more than peptide producers?

A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis

Inhibitors for the Immuno-and Constitutive Proteasome: Current and Future Trends in Drug Development

Immunoproteasomeselective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma

Proteasome Inhibitor PS-341 Inhibits Human Myeloma Cell Growth in vivo and Prolongs Survival in a Murine Model

Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells

LMP2-Specific Inhibitors: Chemical Genetic Tools for Proteasome Biology

Inhibitor-binding mode of homobelactosin C to proteasomes: New insights into class I MHC ligand generation

Exploiting nature's rich source of proteasome inhibitors as starting points in drug development

Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib

Tripeptide mimetics inhibit the 20 S proteasome by covalent bonding to the active threonines

Systematic Comparison of Peptidic Proteasome Inhibitors Highlights the α-Ketoamide Electrophile as an Auspicious Reversible Lead Motif

Schmidt, alpha-Keto phenylamides as P1'-extended proteasome inhibitors

Prime Site Binding Inhibitors of a Serine Protease: NS3/4A of Hepatitis C Virus

Exploring the S4 and S1 Prime Subsite Specificities in Caspase-3 with Aza-Peptide Epoxide Inhibitors

HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2′ Ligands To Optimize Hydrogen Bonding in the Substrate Envelope

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Proteasome inhibition in vivo promotes survival in a lethal murine model of severe acute respiratory syndrome

The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle

Severe Acute Respiratory Syndrome Coronavirus Replication Is Severely Impaired by MG132 due to Proteasome-Independent Inhibition of M-Calpain

Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Methyl 2-Furoate: An Alternative Reagent to Furan for Palladium-Catalysed Direct Arylation

Synthesis, structures and catalytic activity of Pd(II) saccharinate complexes with monophosphines in direct arylation of five-membered heteroarenes with aryl bromides

Synthesis and Biological Activity of Peptide α-Ketoamide Derivatives as Proteasome Inhibitors

Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors

Selective inhibition of the immunoproteasome by ligand-induced crosslinking of the active site

Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability

The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design

GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Calcium-bound structure of calpain and its mechanism of inhibition by calpastatin

Cell-Based Optimization of Covalent Reversible Ketoamide Inhibitors Bridging the Unprimed to the Primed Site of the Proteasome beta5 Subunit

SREBPdependent lipidomic reprogramming as a broad-spectrum antiviral target

Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19)

Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system

Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus

Exploring the Proteolysis Mechanism of the Proteasomes

The cell based proteasome inhibition were assayed following the promega protocol. 

RPMI8226, Ramos，THP-1 were grown in RPMI 1640 supplemented with 10% fetal bovine serum at 37 °C in 5% CO 2 . MGC-803, Hela, SW480 were grown in DMEM supplemented with 10% fetal bovine serum at 37°C in 5% CO 2 .A standard MTS assay was used to measure cancer cell growth. A 100 μL RPMI8226(1*10 4 /well), THP-1(5*10 4 /well), Ramos (5*10 4 /well), MGC-803 (5*10 3 /well), Hela (5*10 3 /well), SW480 cells (5*10 3 /well) were seeded into 96-well plates. After treated with tested compounds for 72 h, an amount of 20 μL of a solution of MTS was added to each well and

This work was supported by the grant from Guangdong province (grant no. 00201503).